CDR3 develops stem cell-based immunotherapies to cure HPV-related cancers using chimeric antigen receptors or chronic viral infections using T cell receptors.
Market:
Today, we lack cures for most virus-related cancers and chronic viral infections, especially from human papillomavirus, or HPV, and cytomegalovirus, or CMV, which can be fatal for those with weakened immune systems. CDR3’s stem cell-based treatments target HPV-associated cancers, a $16.3B market in 2018 growing at 4.5% yearly, and chronic viral infections, a rapidly growing market estimated to reach $44.2B by 2026 — with chronic CMV alone a $1.2B market in 2020 growing at 12.3% yearly.
Technology:
CDR3’s patented technology alters blood stem cells to add chimeric antigen receptors (CARs) or T cell receptors (TCRs) that enable the body’s natural defenses to target virus-associated cancers. These stem cells engraft in bone marrow and develop, normally and continuously, into T cells. Isolating a patient’s own cells and infusing the CAR/TCR gene therapy creates a permanent source of T cells expressing the CAR/TCR, avoiding the high cost and significant limitations of current T cell therapy approaches.
Advantages:
- Stem cell-based approach
- Limited manipulation and cell expansion
- Long-term engraftment
- Cells develop naturally in the body
- Produces persistent, functional T cells
Development Stage:
- Pre-clinical
Patents Issued:
- US 9,228,007 B1 - RECOMBINANT HUMAN PROGENITOR CELLS, ENGINEERED HUMAN THYMOCYTES, AND ENGINEERED HUMAN T CELLS, issued January 5, 2016
- US 9,951,118 B2 - ENGINEERING ANTIVIRAL T CELL IMMUNITY THROUGH STEM CELLS AND CHIMERIC ANTIGEN RECEPTORS, issued April 24, 2018
- US 2020/0061117 A1 - PROTECTIVE CHIMERIC ANTIGEN RECEPTOR STEM CELL GENE THERAPY FOR VIRAL INFECTION, filed May 4, 2018
- PCT/US2020/055 1 94 - CHIMERIC ANTIGEN RECEPTORS AGAINST HUMAN CYTOMEGALOVIRUS, priority date October 11, 2019
Select Publications:
- Cancer-fighting gene immunotherapy shows promise as treatment for HIV. Artificial receptors kill cells infected with the virus that causes AIDS, UCLA study finds | UCLA Newsroom
- Gene therapy using CAR T cells could provide long-term protection against HIV | UCLA Health
- Researchers devise more efficient, enduring CAR gene therapy to combat HIV | UCLA Newsroom
- CIRM funding helps improve immune cell therapy to combat HIV | The STEM Cellar
Contact:
Website: cdr3therapeutics.comPhone: 925-765-8205
Email: matt@lorence.tech
- Active Membranes, LLC.
- Avesta76 Therapeutics
- Capacity Bio
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- EarlyDx
- Forcyte Biotechnologies
- Gradient Orthodontics
- ImmunoVec
- Lactation Lab
- Lookin, Inc.
- Nanoarmor, LLC.
- Partillion Bioscience Corporation
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Scarless Laboratories
- Sorriso Pharmaceuticals
- Symphony Biosciences
- Vault Pharma
- ViBo Health
- Westwood Bioscience